Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.

Autor: Neiheisel A; College of Pharmacy, California Health Sciences University, Clovis, California, USA., Kaur M; College of Pharmacy, California Health Sciences University, Clovis, California, USA., Ma N; College of Pharmacy, California Health Sciences University, Clovis, California, USA., Havard P; Kaweah Health Foundation, Kaweah Health, Visalia, California, USA., Shenoy AK; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Health Sciences University, Clovis, California, USA.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2022 Mar 01; Vol. 150 (5), pp. 727-740. Date of Electronic Publication: 2021 Oct 11.
DOI: 10.1002/ijc.33811
Abstrakt: Wnt signaling plays an essential role in the initiation and progression of various types of cancer. Besides, the Wnt pathway components have been established as reliable biomarkers and potential targets for cancer therapy. Wnt signaling is categorized into canonical and noncanonical pathways. The canonical pathway is involved in cell survival, proliferation, differentiation and migration, while the noncanonical pathway regulates cell polarity and migration. Apart from its biological role in development and homeostasis, the Wnt pathway has been implicated in several pathological disorders, including cancer. As a result, inhibiting this pathway has been a focus of cancer research with multiple targetable candidates in development. In this review, our focus will be to summarize information about ongoing and completed clinical trials targeting various Wnt pathway components, along with describing current and emerging Wnt targeted therapies. In addition, we will discuss potential opportunities and associated challenges of inhibiting Wnt signaling for cancer therapy.
(© 2021 UICC.)
Databáze: MEDLINE
Externí odkaz: